Previous 10 | Next 10 |
Presented clinical and preclinical data at Alzheimer’s Association International Conference 2022 Strong balance sheet to support clinical development pipeline BOTHELL, Wash., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-s...
Additional data showed numerical improvement in activities of daily living (ADCS-ADL23), a protocoled secondary endpoint and a functional measure of independence Plasma biomarker data in a pre-specified subgroup analysis showed a statistically significant reduction in neurofilam...
F osgo-AM, the active metabolite of Fosgonimeton (ATH-1017), demonstrates neuroprotective effects in primary neuron cultures New orally available small molecule positive modulators of HGF/MET reverse memory deficits in preclinical models BOTHELL, Wash., Aug. 02, 2022 (GLOB...
BOTHELL, Wash., July 25, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the details of its participation at the Alzh...
Biopharmaceutical companies Athira Pharma ( ATHA ) and BioXcel Therapeutics ( BTAI ) have outperformed the gains in the biotech space on Thursday after Mizuho launched their coverage on small and mid-cap names focused on the central nervous system (CNS). Despite being a high...
Gainers: Inhibrx ( INBX ) +5% . Maxeon Solar Technologies ( MAXN ) +4% . Applied Molecular Transport ( AMTI ) +4% . Enovix Corporation ( ENVX ) +3% . Malibu Boats ( MBUU ) +3% . Losers: Kornit Digital ( KRNT ) -21% ...
Mid- and late-stage data readouts over the last few years for Alzheimer's therapies have had a similar theme: Failure. Almost all these candidates have one thing in common: They target reducing beta-amyloid plaque in the brain that is thought to play a role in the memory-robbing dis...
JMP Securities has lowered its rating on Athira Pharma (NASDAQ:ATHA) to Market Perform from Market Outperform after the clinical-stage biotech said that its lead product candidate, fosgonimeton did not meet key goals in a mid-stage trial for mild-to-moderate Alzheimer’s disease (AD). W...
Sadly, it's not really news when a biopharma company has an Alzheimer's clinical trial failure. Objectively, fosgonimeton would appear to be done. So we have a failed Alzheimer's clinical candidate, and what may well be a failed target idea entirely. For further details see:...
Athira Pharma has just read out first Phase 2 results in one of two Alzheimer’s trials. Its drug candidate ATH-1017 targets the HGF/MET pathway, a unique approach which has led to promising Phase 1 data. The readout shows efficacy in a subgroup, underlining validity of the ...
News, Short Squeeze, Breakout and More Instantly...
Reporting of Topline Results Targeted by End of Third Quarter 2024 Results to be presented in oral presentation at Clinical Trials on Alzheimer’s Disease (CTAD) on October 29, 2024, in Madrid, Spain BOTHELL, Wash., July 09, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc (N...
Company to provide overview of Phase 2/3 LIFT-AD clinical trial of fosgonimeton in mild-to-moderate Alzheimer’s disease (AD); LIFT-AD topline data expected in second half of 2024 Two key opinion leaders will discuss ongoing unmet medical need and LIFT-AD’s primary endpoint...
BOTHELL, Wash., June 11, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that it has completed the first cohort of healthy ...